- Eisai, Biogen Alzheimer’s drug Leqembi would cost US Medicare up to $5 bln a year, study finds Reuters
- Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates CNBC
- Alzheimer’s drug lecanemab could boost Medicare spending by $5B a year: study FierceHealthcare
- Annual Costs of Lecanemab Estimated to Be Upwards of $2B Medscape
- Medicare, FDA urged to press ahead with new Alzheimer’s drug Leqembi The Hill
- View Full Coverage on Google News
Source link